Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday that the first patient has been enrolled in a clinical trial evaluating bemcentinib, its AXL kinase inhibitor, in combination with pacritinib, a JAK2 inhibitor.
The trial, sponsored by the Mays Cancer Center at UT Health San Antonio, will investigate this combination therapy in patients with lung adenocarcinoma.
Pacritinib is marketed in the United States as VONJO and is owned by biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI).
The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
Akeso's Penpulimab receives Chinese regulatory approval
Korro Bio receives FDA orphan drug designation for KRRO-110
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Polarean expands Xenon MRI imaging for pharma-sponsored research
Celltrion's OMLYCLO receives US FDA approval
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial